Business Wire

MA-BVI

4.10.2021 14:03:01 CEST | Business Wire | Press release

Share
BVI Announces Investment & Collaboration with Beyeonics Vision

BVI , a purpose-built diversified global ophthalmic device company, today announced an investment in Beyeonics Vision, a medical technology subsidiary of Elbit Systems Ltd. (NASDAQ: ESLT and TASE: ESLT) ("Elbit Systems"). Beyeonics Vision uses integrated augmented reality, tracking, and image processing/AI platforms to deliver improved visualization, optimized workflow, and real-time support to surgeon decision-making process in the operating room. The collaboration also promotes a streamlined process to commercialize Beyeonics™ One in the United States, with potential for rapid expansion in territories outside of the United States.

“BVI routinely assesses opportunities to partner with companies that have a commitment to innovation and share our entrepreneurial mindset. With Beyeonics One, BVI can expand our offering of unparalleled surgical experience during anterior and posterior segment procedures,” said Shervin Korangy, BVI’s President and Chief Executive Officer. “We know from experience that it takes shared priorities to deliver on our mission and are excited that Beyeonics Vision shares our passion for and commitment to refocusing the future of vision.”

Beyeonics Vision has been developing Beyeonics One, the first and only commercial ophthalmic digital imaging system to replace optical analog microscopes. Beyeonics One is an open and upgradable digital visualization platform, equipped with an ultra-high-resolution camera that processes and transfers digitally enhanced images to a high-resolution head-wearable display for a truly immersive and natural stereoscopic 3-D viewing experience. Beyeonics One provides surgeons with enhanced automation, programming autonomy and more freedom to set-up the operating room and adopt a more ergonomically efficient posture. Additionally, the system enables real-time decision-making process with customizable integration of accessible pre-/intra-operative data and seamless integration with other devices.

“We are excited to partner with BVI on the U.S. commercialization of Beyeonics One and the potential to collaborate on future innovations as well. Through this collaboration we aim to expand our collective capabilities to optimize all aspects of visualization for eye surgeons and offer a transformative experience to providers and patients,” shared Ron Schneider, CEO of Beyeonics Vision.

BVI first previewed their partnership with Beyeonics Vision at the American Society of Cataract and Refractive Surgery annual meeting in July 2021 and will continue this at ESCRS in Amsterdam in October, & AAO in New Orleans in November.

About BVI

BVI® is a global ophthalmic medical device manufacturer with a mission to deliver high quality solutions and innovation for advancing eye surgery and improving the vision of patients. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams, in more than 115 countries worldwide, either directly or through our network of trusted distributors. Our trusted brands include: Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-Use Instruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs).

About Beyeonics Vision

Beyeonics™ Vision, a subsidiary from Elbit Systems (NASDAQ:ESLT), is a medical technology company developing surgeon-centered visualization solutions. Beyeonics is aiming to consolidate & democratize surgery, deliver a transformative technology by using integrated augmented reality, tracking and image processing visualization platform to tell surgeons valuable information, to guide decisions and to perform automatic tasks.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye